tbuckley/cabot-search huggingface dataset:
Louis Berlioz (1776–1848)
Authors: S. J. London
Journal: New England Journal of Medicine (1964)

BY the accepted patterns of life under the Hippocratic tradition, it is not at all unusual for a physician to achieve fame via the inspiration and guidance of a younger man, whether a stranger or a son. It is, however, most unusual for him to have done so through a son whose calling is quite far afield from medicine. Such was the lot of Dr. Louis Berlioz, whose legacy to the world was his famous composer son, Hector.Hector Berlioz was the first of the great Romantic composers, which is by way of saying that he was the first to . . .
John Clarke (1609–1676)
Authors: S. Gerald Sandler
Journal: New England Journal of Medicine (1963)

MORE than a hundred and twenty years before the Bill of Rights guaranteed religious freedom throughout the American Colonies, the citizens of the Rhode Island Colony petitioned Charles II of England for a charter that would ensure territorial rights within a framework of civil and religious liberties. This year marks the three-hundredth anniversary of the signing of the consequent Rhode Island Charter of 1663, which became the first comprehensive doctrine of religious and political freedom in the New World. The drafting of a charter of individual liberties at this early date was unprecedented and has prompted the claim that "to . . .
Effect of L-Arginine on Plasminogen-Activator Inhibitor in Hypertensive Patients with Hypercholesterolemia
Authors: Richard Korbut, Krzysztof Bieron, Richard J. Gryglewski
Journal: New England Journal of Medicine (1993)

To the Editor: Vascular endothelium converts L-arginine to nitric oxide. An increase in blood pressure after the inhibition of nitric oxide synthase suggests that a deficiency of nitric oxide may contribute to the pathogenesis of hypertension1. Indeed, exogenous L-arginine produces systemic hypotension in patients with essential hypertension2. Sodium nitroprusside (a nitric oxide donor) inhibits the release of plasminogen-activator inhibitor (PAI) from platelets and has fibrinolytic properties3. Plasma PAI activity is increased in patients with hypertension, venous thrombosis, and recurrent myocardial infarction4. L-Arginine hydrochloride (Boehringer-Mannheim), at a daily dose of 60 mmol given over a three-hour period, . . .
An Analysis of the Reporting of Results in Lung Cancer Drug Trials
Authors: Seth A. Rudnick, Alvan R. Feinstein
Journal: JNCI Journal of the National Cancer Institute (1980)

Journal Article An Analysis of the Reporting of Results in Lung Cancer Drug Trials Get access Seth A. Rudnick, Seth A. Rudnick Search for other works by this author on: Oxford Academic PubMed Google Scholar Alvan R. Feinstein Alvan R. Feinstein Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 64, Issue 6, June 1980, Pages 1337–1343, https://doi.org/10.1093/jnci/64.6.1337 Published: 01 June 1980 Article history Received: 14 September 1979 Accepted: 19 November 1979 Published: 01 June 1980
Modeling and Analyses to Identify Potential Dosing Regimens of DX-2930 for the Long-Term Prophylaxis of Hereditary Angioedema
Authors: H. James Wedner, Paula J. Busse, Aleena Banerji, Mustafa Shennak, William R. Lumry, Mark A. Davis-Lorton, Joshua S. Jacobs, James W. Baker, Jonathan A. Bernstein, Richard F. Lockey, H. Henry Li, Timothy J. Craig, Marco Cicardi, Marc A. Riedl, Ahmad Al-Ghazawi, Carolyn Soo, Ryan Iarrobino, Daniel Sexton, Christopher TenHoor, Ryan Faucette, Joseph C. Biedenkapp, Yung H. Chyung, Burt Adelman
Journal: Journal of Allergy and Clinical Immunology (2016)
Choosing Wisely Recommendations Using Administrative Claims Data—Reply
Authors: Abiy Agiro, Andrea DeVries, Alan Rosenberg
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Characterising Unintended Effects of Genetic Modification on Expression of Gluten Proteins Involved in IgE-Mediated Allergies and Coeliac Disease Using Proteomics
Authors: Sophie N.L. Bromilow, Lee Gethings, Peter Shewry, Mike Bromley, Michael Buckley, E.N. Clare Mills
Journal: Journal of Allergy and Clinical Immunology (2016)
Alpha-Beta Thalassemia Disease in a Negro Family
Authors: Howard A. Pearson
Journal: New England Journal of Medicine (1966)

CONVINCING evidence has been presented that the term thalassemia does not describe a specific or homogeneous entity. Bather, it refers to a group of heritable defects of hemoglobin synthesis manifested by hypochromic microcytic anemia. The most clearly defined of these have been designated respectively as α thalassemia and β thalassemia because the genetically determined blocks of hemoglobin synthesis primarily affect these polypeptide subunits.1 β-thalassemia in the heterozygous state is characterized by significant elevations of hemoglobin A2 in more than 90 per cent of cases.2 , 3 This form of thalassemia "interacts" with abnormal β-chain hemoglobin genes to produce a hematologic disease . . .
The Borealis-2 clinical trial: A randomized phase II study of OGX-427 plus docetaxel versus docetaxel alone in relapsed/refractory metastatic urothelial cancer.
Authors: Jonathan E. Rosenberg, Noah M. Hahn, Meredith M. Regan, Cindy Jacobs, Patricia S. Stewart, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2013)

TPS4588^ Background: Heat shock protein 27 (Hsp27) is over-expressed in many cancers including bladder, lung, prostate, and breast. Increased Hsp27 has been associated with inhibition of chemotherapy-induced apoptosis, increased tumor cytoprotection, and development of treatment resistance. OGX-427 is an antisense oligonucleotide designed to bind Hsp27 mRNA, inhibiting production of the Hsp27 protein. Inhibition of Hsp27 has been shown to increase apoptosis, inhibit tumor growth, and sensitize tumor cells to chemotherapy in a variety of malignancies, including urothelial cancer. Results of preclinical and phase 1 studies suggest that addition of OGX-427 to chemotherapy is well tolerated and may improve treatment efficacy. BOREALIS-2 is a randomized, multicenter, phase 2 study of OGX-427 in combination with docetaxel (DOC) vs. DOC alone in locally advanced/metastatic bladder cancer patients who received at least one line of prior platinum-based therapy. The primary objective is to evaluate overall survival. Secondary objectives include comparisons of safety and tolerability, disease response, and serum levels of Hsp27 and other pathway-related proteins. Associations between clinical outcomes, levels of Hsp27 and other proteins, and circulating tumor cells will be evaluated. Methods: Patients (N=200) are randomized in a 1:1 ratio following stratification (time from prior systemic chemotherapy; Bellmunt criteria). Up to 2 prior systemic therapies are allowed. Treatment-arm patients receive three loading doses of OGX-427 (600 mg) followed by up to ten 21-day treatment cycles (OGX-427 1000 mg on Days 1, 8, and 15 and DOC 75 mg/M 2 IV on Day 1). Control-arm patients receive DOC 75 mg/M 2 IV on Day 1 of each cycle. Treatment may continue until disease progression, unacceptable toxicity, completion of 10 cycles, or patient withdrawal. Patients who discontinue DOC due to toxicity after ≥2 cycles and do not have disease progression may receive maintenance therapy with OGX-427. One interim futility analysis will be performed. The trial will not be stopped early based on efficacy. Clinical trial information: NCT01780545.
S25 Establishing a normal range in driving simulator performance using standard deviation of lane position (SDLP) in an advanced PC –based driving simulator (MiniUoLDS)
Authors: A Dwarakanath, D Ghosh, SL Baxter, PD Baxter, MW Elliott
Journal: Thorax (2015)

<h3>Introduction</h3> Some patients with OSAS are at higher risk of being involved in road traffic accidents. No objective tests have been shown to predict reliably whether an individual is safe to drive or not and there is significant variation in the advice given by the clinicians. Using a continuously measured variable (SDLP) on an advanced PC-based driving simulator the at risk patients can be identified with a high degree of accuracy. We have now compared driving performance based on SDLP in controls and untreated OSAS patients and have established a normal range. <h3>Methods</h3> 129 untreated male OSAS patients (Age 53+/-12, ESS 14+/-5, ODI 41+/-26, BMI 36+/-8,) and 79 male controls (Age 56+/-15, ESS 4+/-3, BMI 28+/-8) were recruited in the study. All performed a simulator run after initial acclimatisation. The simulator run consisted of eight epochs and on average needed 7 min to complete one epoch driving at 70 miles per hour. The simulator layout was designed in line with the UK highways agency road standards. The mean SDLP in epoch-3 (SDLP3) was compared between the two groups using unpaired T-test. The SDLP3 in the patient group was evaluated and this was compared with the mean and 95<sup>th</sup> centile values of SDLP 3 among the controls. <h3>Results</h3> There was a significant difference in SDLP3 between OSAS patients and controls (0.44 v/s 0.39, P = 0.03). 10% of patients had worse SDLP3 than the 95<sup>th</sup> centile among controls (Figure 1). <h3>Conclusions</h3> Worse SDLP is a marker of poor driving performance and this is significantly worse in untreated OSAS patients as compared to controls. The choice of 95% is arbitrary but is consistent with the approach taken to establish a normal range. Establishing where a patient lies in comparison to controls may be useful in advising patients whether they are at increased risk of an accident due to OSAS. Defining a normal range based on continuously measured variable in MiniUoLDS holds promise and is a step ahead towards developing an objective test in evaluating the at risk OSAS patients.
The Combined Effect of 3-Methylcholanthrene and N,N′-2,7-fluorenylenebisacetamide on the Induction of Cancer of the Glandular Stomach of the Rat
Authors: Harold L. Stewart, Katharine C. Snell, Harold P. Morris
Journal: JNCI Journal of the National Cancer Institute (1965)

Journal Article The Combined Effect of 3-Methylcholanthrene and N,N′-2,7-fluorenylenebisacetamide on the Induction of Cancer of the Glandular Stomach of the Rat Get access Harold L. Stewart, Harold L. Stewart Search for other works by this author on: Oxford Academic PubMed Google Scholar Katharine C. Snell, Katharine C. Snell Search for other works by this author on: Oxford Academic PubMed Google Scholar Harold P. Morris Harold P. Morris Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 34, Issue 2, February 1965, Pages 157–174, https://doi.org/10.1093/jnci/34.2.157 Published: 01 February 1965 Article history Received: 03 June 1964 Published: 01 February 1965
A Physiologic Approach to the Diagnosis of Acute Pulmonary Embolism
Authors: Eugene D. Robin, Desmond G. Julian, David M. Travis, Charles H. Crump
Journal: New England Journal of Medicine (1959)

ACUTE pulmonary embolism occurs frequently, but its diagnosis is difficult. Its recognition in practice depends largely upon the signs and symptoms of infarction rather than the presence of pulmonary vascular occlusion. Available diagnostic evidence includes an appropriate history, suggestive physical signs and radiologic and electrocardiographic changes, which are helpful if nonspecific. Pulmonary embolism without infarction is particularly difficult to diagnose definitively, and may simulate many kinds of cardiac, pulmonary, pleural, neurologic and acute abdominal disease.1 The need for a technic that will assist in this difficult diagnosis is clear. This paper describes an approach to the problem, emphasizing the principles, . . .
Increased Expression of miR-23a Mediates a Loss of Expression in the RAF Kinase Inhibitor Protein RKIP
Authors: Stefan Hatzl, Olivia Geiger, Maja Kim Kuepper, Veronica Caraffini, Till Seime, Tobias Furlan, Erika Nussbaumer, Rotraud Wieser, Martin Pichler, Marcel Scheideler, Katarzyna Nowek, Mojca Jongen-Lavrencic, Franz Quehenberger, Albert Wölfler, Jakob Troppmair, Heinz Sill, Armin Zebisch
Journal: Cancer Research (2016)

RAF kinase inhibitor protein (RKIP) is a seminal regulator of intracellular signaling and exhibits both antimetastatic and antitumorigenic properties. Decreased expression of RKIP has been described in several human malignancies, including acute myelogenous leukemia (AML). As the mechanisms leading to RKIP loss in AML are still unclear, we aimed to analyze the potential involvement of miRNAs within this study. miRNA microarray and qPCR data of more than 400 AML patient specimens revealed correlation between decreased expression of RKIP and increased expression of miR-23a, a member of the miR-23a/27a/24-2 cluster. In functional experiments, overexpression of miR-23a decreased RKIP mRNA and protein expression, whereas miR-23a inhibition caused the opposite effect. By using an RKIP 3'-untranslated region luciferase reporter construct with and without mutation or deletion of the putative miR-23a-binding site, we could show that RKIP modulation by miR-23a is mediated via direct binding to this region. Importantly, miR-23a overexpression induced a significant increase of proliferation in hematopoietic cells. Simultaneous transfection of an RKIP expression construct lacking the miR-23a-binding sites reversed this phenotype, indicating that this effect is truly mediated via downregulation of RKIP. Finally, by analyzing more than 4,300 primary patient specimens via database retrieval from The Cancer Genome Atlas, we could highlight the importance of the miR-23a/RKIP axis in a broad range of human cancer entities. In conclusion, we have identified miR-23a as a negative regulator of RKIP expression in AML and have provided data that suggest the importance of our observation beyond this tumor entity. Cancer Res; 76(12); 3644-54. ©2016 AACR.
Abstract A47: Unusual suspects identified in neuroblastoma: An unexpected tumor suppression pathway
Authors: Zhang'e Choo, Rachel Yu Lin Koh, Karin Wallis, Timothy Jia Wei Koh, Chik Hong Kuick, Veronica Sobrado, Amos Hong Pheng Loh, Shui Yen Soh, Susanne Schlisio, Kenneth Tou En Chang, Zhi Xiong Chen
Journal: Cancer Research (2016)

Abstract Developmental apoptosis of neural crest precursors is crucial in determining the final number of terminally differentiated cells such as sympathetic neurons. During neural development, cells undergo apoptosis as NGF becomes limiting. Aberrant developmental apoptosis is implicated in pediatric sympathetic nervous system tumors. When NGF becomes limiting, a developmental apoptotic pathway is activated which requires KIF1Bbeta. KIF1Bbeta is necessary and sufficient for apoptosis during NGF withdrawal. KIF1Bbeta maps to 1p36.2, a frequently deleted region in neuroblastomas, and a neural crest-derived cancer. We identified that KIF1Bbeta-induced apoptosis requires RNA/DNA helicase DHX9. KIF1Bbeta interacts with DHX9 to enhance translocation and accumulation of cytoplasmic DHX9 in the nucleus, resulting in transcription of apoptotic XAF1. Transcription-incompetent DHX9 is unable to potentiate KIF1Bbeta-induced cell death. Knockdown of DHX9 also protects from KIF1Bbeta-induced cell death whereas KIF1Bbeta loss-of-function domains or patient-associated point mutants are unable to translocate and accumulate cytoplasmic DHX9 in the nucleus, impairing XAF1 expression. Furthermore, XAF1 silencing protects from KIF1Bbeta-induced and NGF withdrawal-mediated apoptosis in vitro as well as promotes tumor growth in vivo whereas XAF1 overexpression is necessary and sufficient to induce apoptosis in vitro and delays tumor growth in vivo. Conditional knockout of KIF1Bbeta in the superior cervical ganglia neurons of mouse pups also specifically ablates XAF1 expression in vivo and ex vivo, suggesting that KIF1Bbeta and XAF1 are tightly regulated and act along the same pathway. Clinically, tissue microarray analysis of pre-treatment or post-treatment neuroblastoma patients who are 1p-intact or 1p-deleted, revealed strong prognostic significance of XAF1 expression in disease stratification. Our findings provide a mechanistic understanding on the development of neuroblastoma through unexpected candidates of tumorigenesis. Citation Format: Zhang'e Choo, Rachel Yu Lin Koh, Karin Wallis, Timothy Jia Wei Koh, Chik Hong Kuick, Veronica Sobrado, Amos Hong Pheng Loh, Shui Yen Soh, Susanne Schlisio, Kenneth Tou En Chang, Zhi Xiong Chen. Unusual suspects identified in neuroblastoma: An unexpected tumor suppression pathway. [abstract]. In: Proceedings of the AACR Special Conference on Advances in Pediatric Cancer Research: From Mechanisms and Models to Treatment and Survivorship; 2015 Nov 9-12; Fort Lauderdale, FL. Philadelphia (PA): AACR; Cancer Res 2016;76(5 Suppl):Abstract nr A47.
Blood-Volume Estimates in Coombs-Test-Positive Infants
Authors: Yves W. Brans, Rachel R. Milstead, Penrhyn E. Bailey, George Cassady
Journal: New England Journal of Medicine (1974)

Blood volume (estimated from the 10-minute T-1824 albumin space and mixed venous hematocrit) was determined before exchange transfusion in 32 neonates with nonhydropic Coombs-test-positive hemolytic disease. Rhesus or ABO incompatibility was commonly accompanied by perinatal asphyxia, anemia, elective prematurity and operative delivery. Although neonates with hemolytic disease are generally believed to be hypervolemic, this study suggests that they are normovolemic if premature and hypovolemic at maturity. Blood volume was linearly related to hematocrit (r = 0.616, p<0.001), but it was not affected by mode of delivery, degree of perinatal asphyxia or postnatal study age. These data suggest that common clinical practices such as denial of placental transfusion, venesection and maintenance of a volume deficit after exchange transfusion should be avoided. (N Engl J Med 290:1450–1452, 1974)
Case 17-2003
Authors: Martin S. Hirsch, Barbara Werner
Journal: New England Journal of Medicine (2003)

Presentation of CaseA 38-year-old woman was admitted to the hospital in early August 2002 because of fever and confusion.The patient had been well until four days earlier, when a headache gradually developed and increased in intensity, accompanied by mild photophobia and stiffness of the neck. Two days before admission, she believed that she was mildly febrile. The day before admission, she was examined at another facility, where she was told she had a “viral illness.” She was given fluids intravenously and was discharged. On the morning of admission, she awoke with shaking chills and a temperature of 40°C. . . .
Downregulation of Cytokines and Chemokines By GB Virus C after Transfusion-Transmission in HIV+ Blood Recipients
Authors: Marion Lanteri, Farnaz Vahidnia, Sylvia Tan, Jack Stapleton, Philip J. Norris, John W. Heitman, Xutao Deng, Sheila Keating, Donald Brambilla, Michael Busch, Brian Custer
Journal: Blood (2014)
Differential Effects of β-Naphthoflavone and Pregnenolone-16α-carbonitrile on Dimethylnitrosamine-Induced Hepatocarcinogenesis&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: Mary F. Argus
 4, Cornelia Hoch-Ligeti, Joseph C. Arcos, Allan H. Conney
Journal: JNCI Journal of the National Cancer Institute (1978)

The effect of administration of β-naphthoflavone (β-NF) or pregnenolone-16α-carbonitrile (PCN) on the hepatocarcinogenicity of dimethylnitrosamine (DMN) in male SD rats was explored. Both β-NF and PCN are potent repressors of the low Michaelis constant enzymatic form of DMN-demethylase, a mixed-function oxidase that catalyzes DMN demethylation. DMN-induced hepatocarcinogenesis was inhibited by PCN and was enhanced by β-NF. Seven liver tumors were found in 45 rats fed DMN plus PCN compared to 14 liver tumors in 43 rats fed DMN alone; 32 liver tumors were found in 43 rats fed DMN plus β-NF. No liver tumors were detected in rats that received only PCN, β-NF, or the administration vehicles. Of the 53 liver tumors observed, 53% were angiosarcomas; this type of tumor was found in all 3 groups of rats that received DMN.
Case 39-1992
Authors: Richard C. Cabot, Robert E. Scully, Eugene J. Mark, William F. McNeely, Betty U. McNeely, D. Steinberg, N.L. Harris
Journal: New England Journal of Medicine (1992)

Presentation of CaseA 49-year-old woman was admitted to the hospital because of severe abdominal pain, vomiting, and weight loss.The patient was well until six years earlier, when splenomegaly was found. The hematocrit ranged up to 55.1 percent, the white-cell count to 11,500 ( 11.5× 109 per liter), and the platelet count to 717,000 (717×109 per liter). A nephrotomographic examination and echocardiographic study were negative. A diagnosis of polycythemia vera was made; phlebotomy was performed on three occasions, and the hematocrit thereafter remained normal.Five years before admission alopecia developed. One year later the patient began to experience progressive . . .
Case 34-1973
Authors: Richard C. Cabot, Benjamin Castleman, Robert E. Scully, Betty U. McNeely, H. William Scott, Benjamin Castleman
Journal: New England Journal of Medicine (1973)

Presentation of Case*A 68-year-old man was admitted to the hospital because of an abdominal mass.For many years he had been troubled by an irritable colon, with recurrent bouts of diarrhea, abdominal cramps and occasional minor bleeding that was ascribed to hemorrhoids. Five and a half years before admission sigmoidoscopic examination to 20 cm revealed increased motility, minimal edema and fragility of the blood vessels in the anal canal. One year later severe epigastric pain developed, and an upper gastrointestinal series demonstrated a superficial duodenal ulcer. With frequent use of milk the abdominal pain subsided, but the diarrhea increased . . .
Quantitative Study of the Lactate Dehydrogenase-Elevating Virus in Mouse Embryo Cultures
Authors: H. Clarke Anderson, Vernon Riley, M. A. Fitzmaurice, J. D. Loveless, Philip Wade
Journal: JNCI Journal of the National Cancer Institute (1966)

Serial quantitative measurements of the infective titer of the lactate dehydrogenase-elevating virus, in the supernatant Fluid from infected primary mouse embryo cell cultures, indicate that virus replication occurred in vitro. Virus infectivity of supernatants of mouse-embryo cell cultures was also maintained in vitro for prolonged periods by repeated transfers of infected cell suspensions to fresh primary mouse-embryo cell cultures. Evidence is presented which suggests that replication may also be possible to a limited degree in subcultured mouse embryo cells. No cytopathic eFfect or elevation of supernatant lactate dehydrogenase was observed in any of the infected cell culture.